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Summary
Immune thrombocytopenia (ITP) is thought to result from an aberrant
adaptive autoimmune response, involving autoantibodies, B and T lympho-
cytes, directed at platelets and megakaryocytes. Previous reports have
demonstrated skewed CD4+ T-helper subset distribution and enhanced pro-
duction of pro-inflammatory cytokines such as interleukin 17A and inter-
feron gamma. The role of monocytes (MCs) in ITP is less widely described,
but innate immune cells have a role in shaping CD4+ T-cell phenotypes.
Glucocorticoids (GCs) are commonly used for first-line ITP treatment and
modulate a broad range of immune cells including T cells and MCs. Using
multiparameter flow cytometry analysis, we demonstrate the expansion of
intermediate MCs (CD14++CD16+) in untreated patients with newly diag-
nosed ITP, with these cells displaying a pro-inflammatory phenotype, char-
acterised by enhanced expression of CD64 and CD80. After 2 weeks of
prednisolone treatment (1 mg/kg daily), the proportion of intermediate
MCs reduced, with enhanced expression of the anti-inflammatory markers
CD206 and CD163. Healthy control MCs were distinctly different than
MCs from patients with ITP before and after GC treatment. Furthermore,
the GC-induced phenotype was not observed in patients with chronic ITP
receiving thrombopoietin receptor agonists. These data suggest a role of
MCs in ITP pathogenesis and clinical response to GC therapy.
Keywords: autoimmunity, glucocorticoids, steroids, immune thrombocy-
topenia, monocyte subsets.
Introduction
Immune thrombocytopenia (ITP) is a rare (2–3/100 000)
autoimmune condition characterised by a low platelet count
(<100 9 109/l) with an increased risk of bleeding and fati-
gue.1,2 It can be categorised clinically as newly diagnosed
(<3 months from diagnosis), persistent (3–12 months) or
chronic ITP (>12 months).3,4 High-dose glucocorticoids
(GCs) are the recommended first-line treatment for ITP.
Patients who fail GC treatment, either due to lack of
response, intolerance or relapse after GC is discontinued,
receive second-line treatments, such as thrombopoietin
receptor agonists (TPO-RA), mycophenolate mofetil (MMF)
or rituximab. ITP pathogenesis is driven by B and T cells
through antibody- and cell-mediated mechanisms, targeting
platelets and megakaryocytes, resulting in increased con-
sumption and decreased production of platelets.5–7 Patients
with ITP have elevated interleukin 17A (IL-17A) and inter-
feron gamma (IFN-c) producing CD4+ T cells, as well as
lower numbers of circulating forkhead box P3 (FOXP3)+ reg-
ulatory T cells (Tregs).8–10 Monocytes (MCs) play a key role
in shaping the T-cell response through processes of antigen
presentation and cytokine production.11 The contribution of
MCs to the development of ITP is less well understood than
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classical antibody and T cell-mediated autoimmunity. It is
nonetheless likely that MCs shape these adaptive immune
drivers of ITP, as well as the T-cell response to treatment.
Human MCs are classified into three subsets based on their
cell surface expression of CD14 [lipopolysaccharide (LPS) co-
receptor] and CD16 [activatory Fc gamma receptor III
(FccRIII)] into classical (C-MCs; CD14++CD16), intermedi-
ate (I-MCs; CD14++CD16+) and non-classical (NC-MCs;
CD14+CD16++) MCs.12 In many autoimmune conditions, I-
MCs are enriched13 and in the context of inflammation drive
enhanced memory T-cell proliferation and inflammatory cyto-
kine expression.14,15 CD16+ MCs from patients with ITP have
been shown to specifically promote the expansion of IFN-
c+CD4+ T cells and concomitantly inhibit the proliferation of
Tregs,16 providing evidence that MCs shape T-cell responses in
ITP. However, a detailed MC phenotype in untreated, newly
diagnosed patients with active ITP has not yet been described.
Different MC subsets have unique abilities to shape T cells
with I-MCs from healthy controls (HCs) demonstrating
reduced priming of na€ıve T cells and reduced pro-inflamma-
tory CD4+ T-cell polarisation, while also promoting secretion
of IL-10 by Tregs, implying that I-MCs under homeostatic
conditions attenuate CD4+ T-cell activity.17
GCs, such as prednisolone or dexamethasone (dex), aim
to suppress aberrant immune responses,3,4 and while the T
cell effect of these drugs has been described,18 the effect of
GCs on MC subsets has been less well researched. GC treat-
ment of MCs in vitro induces an expansion of CD16+ MCs
and induction of an anti-inflammatory monocytic pheno-
type, characterised by increased CD163 and CD206 expres-
sion and increased IL-10 production.19-22 However, these
studies did not investigate the in vivo consequences of GC
treatment on MC subsets. Much of the published data
regarding GC effect on immune cellular populations in
patients with autoimmune diseases (including ITP) is limited
by the heterogeneity of patients, including treatment history,
disease severity and chronicity. Study of the in vivo effects of
GC treatment is particularly confounded by these variables.
Given previous reports in other autoimmune diseases and
alongside observations in ITP, we hypothesised that the circu-
lating CD14++CD16+ I-MC subset would have pro-inflamma-
tory characteristics in untreated patients presenting acutely
with active ITP, and that this would be reversed following suc-
cessful GC treatment. In the present study, to further elucidate
the potential role of MCs in disease pathogenesis and resolu-
tion following GC treatment, we examined the phenotype of
the MC subsets before and after in vivo GC treatment in
untreated patients with newly diagnosed ITP.
Patients and methods
Participants
Regulatory approval was granted in accordance with the
NHS Health Research Authority (HRA) at the University
Hospitals Bristol NHS Foundation Trust, UK. Untreated
patients with newly diagnosed ITP, aged ≥16 years, had
peripheral blood samples taken at the point of diagnosis
before treatment and after an average of 2 weeks pred-
nisolone (1 mg/kg daily) treatment, in accordance with inter-
national consensus guidelines.3,4 Additional patients with
varying levels of disease chronicity who had received TPO-
RA therapy, were also recruited (HRA ref: 15/LO/2088). HC
cohorts were recruited at the Bristol Eye Hospital, UHB NHS
Foundation Trust (HRA ref: 04/Q2002/84,). All samples were
obtained following informed written consent in accordance
with the Declaration of Helsinki.
MC and platelet count
Peripheral blood was collected from patients by sterile
venepuncture into ethylenediaminetetraacetic (EDTA) con-
taining tubes. MC and platelet counts were derived from the
full blood count (FBC) processed on the Sysmex XN-20 anal-
yser. Samples were not analysed for anti-platelet autoanti-
bodies.
Human cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
from peripheral blood by density gradient centrifugation
using Ficoll-Paque PLUS (GE Healthcare, Chicago, IL,
USA).TM Human Monocyte Enrichment Cocktail (Stem Cell
Technologies UK, Cambridge, UK) according to the manu-
facturer’s instructions.
MC culture
Isolated MCs were cultured in 24-well low-adherent plates
(Costar, Corning, NY, USA) with 1 lmol/l dex or 100 ng/
ml LPS (Escherichia coli O55:B5) (both Sigma-Aldrich, St.
Louis, MO, USA) at a density of 1 9 106 cells/ml in com-
plete Roswell Park Memorial Institute (RPMI)-1640 supple-
mented with 10% (v/v) fetal calf serum (FCS), L-glutamine,
and penicillin/streptomycin (Gibco, Paisley, SC, UK) for
24 h at 37°C in a 5% humidified CO2 incubator. Cells were
harvested by incubation on ice for 15 min.
Phenotyping by flow cytometry
PBMCs were assessed using a panel of fluorescent-conjugated
antibodies outlined in Table SI. Cultured MCs were har-
vested on ice and stained with CD14, CD16, CD64, CD80,
CD163 and CD206. Analysis was performed on a BD For-
tessa X20 flow cytometer (BD Biosciences, San Jose, CA,
USA). FMO (fluorescence minus one) controls were used for
each fluorochrome. Analysis for t-distributed stochastic
neighbour embedding (t-SNE) and sequential cluster analysis
was performed using FlowJo 10.6.1. The number of MCs
[identified by live, singlets expressing CD4, CD14 and human
E. L. Williams et al.
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leucocyte antigen-DR isotype (HLA-DR)] were equalised, at
random, from each donor and all samples were concatenated
prior to t-SNE analysis. The analysis included 11 markers
outlined in Table SI and excluded CD4, side scatter-area
(SSC-A), forward scatter (FSC)-A, FSC-height (H) and the
live/dead discriminator.
Statistical analysis
Normality of grouped data was determined, and the statistical
significance was assessed by ANOVA (parametric data),
Kruskal–Wallis (non-parametric data) or Friedman (paired,
non-parametric data) using GraphPad PRISM software 8.2.1
(GraphPad Software Inc., La Jolla, CA, USA). Comparison
between individual data sets was determined by either
unpaired t-test (parametric data) or Mann–Whitney test (non-
parametric data) using GraphPad PRISM software 8.2.1.
Results
Intermediate MCs are expanded in untreated patients
with newly diagnosed ITP
The patients with ITP demographics are outlined in Table I.
PBMCs from 11 untreated patients with newly diagnosed
ITP, presenting with a platelet count of <30 9 109/l, were
examined by multiparameter flow cytometry to determine the
MC subset phenotype before and after GC treatment [median
(range) of 13 (8–26) days]. MCs were gated from isolated
PBMCs based on CD4int, CD14 and HLA-DRhi as described by
Abeles et al.23 and shown in Figure S1. Based on CD14 and
CD16 expression (Fig 1A), untreated patients with newly diag-
nosed ITP had an expansion of I-MCs compared with HC
[median (range) age 32 (23–52) years, all female], with a con-
current reduction of the C-MC. The I-MC and NC-MC popu-
lations were reduced after GC therapy, with a concurrent
increase in C-MC (Fig 1A,B). The proportional change in MC
subsets was not reflective of an overall change in total MC
count before or after GC therapy (Fig 1C). There was a signifi-
cant increase in platelet count after GC therapy (Fig 1D).
MCs from patients with newly diagnosed ITP before and
after GC treatment have distinct phenotypes
The phenotypic differences between whole MCs from HCs and
patients with ITP before (ITP pre-GC) and after GC treatment
(ITP post-GC) based on multiparameter flow cytometry were
visualised by generating a t-SNE analysis and summarised in
Table SII. This analysis revealed that MCs from the three
cohorts were markedly different from each other (Fig 2A).
Clustering analysis identified that while some phenotypes were
shared between these cohorts, some cellular clusters were
unique. For example, cluster 12 is only present in untreated
patients with newly diagnosed ITP, whereas cluster 6 is only
observed in patients with ITP after GC therapy (Fig 2B,C).
Detailed examination of these phenotypes in the MC subsets
from untreated patients with newly diagnosed ITP demon-
strates enhanced expression of pro-inflammatory markers
CD64 on all MC subsets and CD80 on C-MCs and I-MCs, but
not NC-MCs compared with HCs. These pro-inflammatory
markers were reduced after GC therapy on the C-MCs and I-
MCs, but not on NC-MCs (Fig 3A,B respectively). CD206 and
CD163 have previously been shown to be upregulated in vitro
and in vivo after GC treatment.21 In the ITP cohort, CD206
was upregulated on all MC subsets (Fig 3C), with CD163 being
specifically upregulated on both I-MCs and NC-MCs, but not
C-MCs (Fig 3D) following in vivo GC treatment. These data
suggest that MCs from newly diagnosed ITP have a pro-in-
flammatory phenotype and that this switches to an anti-in-
flammatory phenotype after treatment, with the nature of this
shift varying between MC subsets.
Changes in CD163 and CD206 associated with GC
therapy are not seen with TPO-RA treatment
To demonstrate that the observed phenotypic changes were
specifically due to GC therapy and not due to disease resolu-
tion, the PBMC phenotype of patients with chronic ITP
receiving TPO-RA treatment (n = 9) was investigated. The
platelet counts for the chronic ITP patient cohort was below







Age, years, median (range) 37 (22–80) 72 (37–81)
Female, n/N 4/11 3/9
Treatment when sample
taken, n/N
Treatment na€ıve* 11/11 n/a
GC* 11/11 n/a







Age, years, median (range) 36 (22–74) 72 (35–86)
Female, n/N 0/4 1/4
Treatment when sample
taken, n/N




No treatment 4/4 1/4
GC, glucocorticoid, ITP, immune thrombocytopenia; MMF,
mycophenolate mofetil; TPO-RA, thrombopoietin receptor agonists.
*11 untreated, newly diagnosed patients had a matched post-gluco-
corticoids (GCs) sample taken on average 13 days after initiation of
therapy (range 8–26 days).
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the normal range, although higher than the counts from the
untreated newly diagnosed cohort (Fig 1D; Figure S2A).
However, MC counts were within normal parameters
(Fig S2B). Consistent with the untreated patients with newly
diagnosed ITP, there was an increase in the proportion of I-
MCs and NC-MCs in patients with ITP treated with TPO-
RA with a decrease in C-MCs compared with the concur-
rently analysed HC cohort [median (range) age 27 (22–
44) years, all female] (Fig 4A). These post-TPO-RA I-MCs
did not express increased CD163 or CD206 compared with
the HCs (Fig 4B,C respectively and Table SIII), suggesting
that expression of these markers on I-MCs is specific to
in vivo GC treatment.
GC treatment in vitro drives an anti-inflammatory MC
phenotype
To corroborate the ex vivo MC phenotype during active
inflammation after diagnosis or after GC therapy, MCs from
HCs [median (range) age 32 (23–58) years, all female] were
treated in vitro with either LPS (to mimic inflammation) or
dex (a synthetic GC) for 24 h under tissue culture condi-
tions. Flow cytometry analysis of in vitro cultured MCs
revealed that, unlike directly ex vivo where three MC subsets
can be detected, there are only two subsets identified: C-MC
and I-MC (Fig 5A). Therefore, further studies were focussed
on only these two MC subsets. Despite previous reports that
GC treatment increases MC viability,20,21 in the present study
there was good viability amongst all groups and therefore
GC treatment did not augment MC survival (Figure S3). In
vitro treatment with dex leads to an enrichment of the I-
MCs compared with both non-treated (NT) and LPS-treated
MCs (Fig 5A,B). This is in contrast with the ex vivo observa-
tions after in vivo GC treatment outlined in Fig 1, but is con-
sistent with our previously reported in vitro data in HCs.17
There was no significant increase in CD64 mean fluores-
cent intensity (MFI) after LPS stimulation compared with
untreated MCs (Fig 5C). However, there was a significant
Fig 1. Intermediate monocytes (MCs) are expanded in untreated patients with newly diagnosed immune thrombocytopenia (ITP). (A) Represen-
tative plots showing the expression of CD14 (LPS receptor) and CD16 (Fc-c receptor) on MC subsets (C, classical; I, intermediate and NC, non-
classical) from peripheral blood MCs isolated from the same untreated patients with ITP (ITP pre; left) and after 2 weeks of glucocorticoid (GC)
treatment (ITP post; right). (B) Cumulative data showing the percentage of each MC subset in healthy controls (HCs), patients with ITP before
and after an average of 2 weeks treatment with 1 mg/kg/daily prednisolone. (C) Peripheral MC counts and (D) platelet counts from the same
untreated patients with ITP and after on average, 2 weeks of GC treatment. Dashed line represents the normal laboratory ranges for each mea-
sure. Sample size = 11 patients with ITP and 10 HCs, mean  SD. [Colour figure can be viewed at wileyonlinelibrary.com]
E. L. Williams et al.
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increase in expression of CD80 on both C-MCs and I-MCs
after treatment with the inflammatory stimulus LPS com-
pared with both NT- and dex-treated MCs (Fig 5D). I-MCs
significantly upregulate CD80 to a greater extent than C-
MCs under the same treatment conditions (Fig 5D). In con-
trast to ex vivo observations, CD206 was not significantly
upregulated after dex treatment (Fig 5E). However, after dex
treatment, I-MCs did have greater CD206 expression than
the C-MCs in the same culture (Fig 5E). After dex treatment,
the I-MCs had significantly upregulated CD163 compared
with NT- and LPS-treated MCs (Fig 5F). In addition, I-MCs
upregulated CD163 to a greater extent after dex treatment
than C-MCs, the latter of which showed a non-significant
increase in CD163 compared with untreated C-MCs or those
stimulated with LPS (Fig 5F). Therefore, these data (sum-
marised in Table SIV) show that while both subsets partly
mimic ex vivo phenotypic changes observed in the untreated
ITP cohort, the I-MCs are most changed after incubation
with either dex or LPS treatment. Furthermore, MCs isolated
from patients with newly diagnosed and chronic ITP and
treated for 24 h with dex, showed similar expansion of
CD16+ I-MCs (Fig 5G). I-MCs significantly upregulated
CD163 compared with C-MCs (Fig 5H); neither MC popula-
tion significantly upregulated CD206 (Fig 5I). This suggests
that MCs from patients with ITP respond similarly to HC
MCs in response to dex in vitro.
Discussion
Studying an untreated newly diagnosed ITP patient cohort
(all patients with initial platelet count of <30 9 109/l) has
avoided confounding factors such as heterogeneous ITP
treatments (current and previous), variable disease severity
and chronicity. Consistent with previous reports, we
observed an expansion of the I-MC population in patients
with active ITP, which returns to a normal proportion of the
peripheral MCs following successful treatment.24 In addition,
we demonstrate that MCs differ in their cell surface pheno-
type in untreated patients with newly diagnosed ITP before
and after GC treatment, and in both cases, compared to HC
samples. However, this does contrast with other autoimmune
diseases, where I-MC expansion is seen after in vivo GC
Fig 2. Ex vivo t-distributed stochastic neighbour embedding (t-SNE) analysis of monocytes (MCs) before and after glucocorticoid (GC) treatment
in patients with untreated immune thrombocytopenia (ITP). (A) t-SNE analysis of healthy controls (HCs), untreated patients with newly diag-
nosed ITP (ITP pre-GC) and paired samples from patients with ITP after GC treatment (ITP post-GC). MCs were conventionally gated, samples
events normalised, and analysis performed based on a 11-colour flow cytometry panel outlined in Table SI. (B) Cluster analysis based was per-
formed and each phenotypic cluster assigned a colour. (C) Heat map examining relative expression of 11-cell surface markers of each subset from
(B). Sample size = 11 patients with ITP and 10 HCs. [Colour figure can be viewed at wileyonlinelibrary.com]
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treatment,17 and suggests that other factors such as different
disease-specific autoimmune context may influence MC phe-
notype before and after exposure to GCs. Variable disease
duration and severity, or co-administration of other therapies
may also play a role. Recently, in a cohort of untreated
patients with ITP, Monzon Manzano et al.25 found an
increased proportion of C-MCs and decreased proportion of
NC-MCs, but in contrast to our present results there was no
change in the percentage of I-MCs. However, the untreated
patients in the Monzon Manzano et al.25 study had ITP for a
minimum of 6 months, some for >12 months, with average
platelet counts of ~100 9 109/l (hence not requiring treat-
ment). This contrasts with our present patients with newly
diagnosed (acute) untreated ITP with platelet counts of
<30 9 109/l and a clinical need for prompt treatment. There-
fore, it is possible that the differences between these cohorts
in terms of disease chronicity, stability and severity of throm-
bocytopenia, explains the differing observations in the MC-
subset proportions. Concordant with our observations, previ-
ous work by Liu et al.26 demonstrated a reduction of CD64
(FccRI) and consequentially a reduction of opsonised bead
phagocytosis, following high-dose in vivo dex treatment. As
expression of Fc receptors contributes to ITP pathogenesis,27
this suggests that reduction of FccRs after GC therapy may
help treat ITP by reducing antibody-mediated platelet phago-
cytosis.
MCs are the precursors of macrophages, the vast diversity
of which has been described as the ‘M1/M2 paradigm’. M1-
like macrophages are characterised by, but not limited to,
expression of CD64 and CD80, with these M1 myeloid cells
being pro-inflammatory and driving type I inflammatory
responses in adaptive immune effector cells. In contrast, M2
Fig 3. Monocyte (MC) subset cell surface expression before and after glucocorticoid treatment in untreated patients with immune thrombocy-
topenia (ITP). Cumulative data showing (A) CD64 mean fluorescent intensity (MFI), (B) percentage CD80, (C) CD206 MFI and (D) CD163
MFI of each MC subset in healthy controls (HCs), patients with ITP before (ITP pre) and after (ITP post) 2 weeks treatment with prednisolone.
Sample size = 11 patients with ITP and 10 HCs, mean  SD. [Colour figure can be viewed at wileyonlinelibrary.com]
E. L. Williams et al.
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macrophages, often expressing CD206 and CD163, are
wound-healing or anti-inflammatory cells.28 Our present
study examined circulating MCs, which can share character-
istics with these M1-like or pro-inflammatory cells and con-
versely M2-like or anti-inflammatory cells. Specifically, we
showed that prior to treatment, all MC subsets showed a
pro-inflammatory, activated phenotype, and this switched to
an anti-inflammatory (or more M2-like) phenotype after
in vivo GC therapy. This suggests that systemic administra-
tion of GCs, rather than MCs returning to a homeostatic
phenotype, skews MCs to be anti-inflammatory. The present
study clarifies that all MCs, in particular I-MCs, have the
ability to be either pro- or anti-inflammatory depending on
the context in which they are activated, shedding light on the
dichotomous role of MCs in both health and disease.
As the ex vivo anti-inflammatory phenotype (namely
CD206 and CD163 upregulation) is not observed with other
therapeutic interventions such as TPO-RAs, we can conclude
that the upregulation of these molecules is due to GC-speci-
fic effects on MCs. This is further supported by previous
reports of CD163 and CD206 upregulation in MCs treated
with GCs in vitro,21,29 and as the in vitro upregulation of
CD163 has been shown in the present study in both patients
with newly diagnosed and chronic ITP, this phenotypic
response to GCs is apparently retained regardless of disease
stage. With regard to the upregulation of CD206 expression
after in vitro dex treatment, our present findings were on the
margins of significance (Fig 5E; P = 00515 compared with
HCs), and given that CD206 regulation by GCs has previ-
ously been examined in murine models or at the genomic
level,21,29,30 further investigation into the kinetics of CD206
protein expression after in vitro GC treatment in human
MCs is warranted. Consistent with our present findings,
Monzon Manzano et al.25 also demonstrated an increase in
I-MCs after TPO-RA treatment, but in contrast to our pre-
sent findings they did not observe an increase in the propor-
tion of NC-MCs or decrease in C-MCs compared with HCs
(this may again simply reflect differences in our patient
cohorts and treatment criteria). Nonetheless, there is a con-
sistent increase in I-MCs across these studies, which may
reflect ongoing ITP disease activity, as following successful
treatment of ITP, MC subsets have previously been found to
return to normal proportions.24,25 Alternatively, increase in
I-MCs may be an indirect TPO-RA effect, as TPO-RAs have
been associated with other immune changes in B , T and
Treg cells, and altered production of anti-platelet autoanti-
bodies.31–33
Under steady state and during acute inflammation, C-
MCs are released from the bone marrow and differentiate
first into I-MCs and secondly into NC-MCs.34 C-MCs are
relatively short-lived (~1 day) and differentiate into I-MCs
and then the NC-MCs in vivo in humans and in humanised
murine models during homeostasis and following acute
inflammatory stimulus.34 In our present study, the observed
expansion of the I-MC populations expressing pro-inflamma-
tory markers is likely a persistent phenotype caused by
enhanced bone marrow egressing C-MCs and the sequential
differentiation into I-MCs due to sustained systemic inflam-
mation. It is not clear whether, after GC treatment, the phe-
notypic shift in the I-MCs and NC-MCs is due to
suppression and phenotype change of circulating MCs or
replacement of the circulating MC populations. Given that I-
Fig 4. Monocytes (MCs) from patients with chronic immune throm-
bocytopenia (ITP) receiving thrombopoietin receptor agonist (TPO-
RA) treatment do not express CD163 and CD206. Cumulative data
showing (A) percentage of MC subsets, (B) CD206 and (C) CD163
mean fluorescent intensity (MFI) expression by each MC subset in
healthy controls (HCs, n = 10), or patients with chronic ITP that
had received TPO-RA (ITP/TPO-RA; n = 9), mean  SD. [Colour
figure can be viewed at wileyonlinelibrary.com]
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MCs and NC-MCs, have been shown to persist in the
periphery longer than C-MCs (~43 and ~74 days respec-
tively) it is most likely that over the 2-week treatment period
the pro-inflammatory MCs (observed before treatment) are
being replaced by fresh bone marrow egressing C-MCs
which, due to the systemic GC therapy, differentiate into the
anti-inflammatory MCs seen post-GC therapy. Previous stud-
ies support this mechanism, demonstrating expansion of a
CD14, CD16 and CD163 population in vitro after GC treat-
ment, with CD163 expression being linked exclusively to GC
treatment.17,21,35,36 However, our present observed reduction
in the percentage of circulating CD16+ MCs after GC
treatment in vivo has also been reported in multiple sclero-
sis37 and in HCs.38 This suggests that there are distinct dif-
ferences with regard to CD16 expression after GC treatment
in vitro and in vivo. In addition, the ex vivo MC phenotype
of untreated newly diagnosed ITP shows an increase in CD64
on all MC subsets, but this is not observed in vitro after LPS
stimulus. LPS treatment in vitro is a single stimulus used to
drive inflammatory myeloid cells but does not reflect the
complex, multifaceted pro-inflammatory stimuli myeloid
cells are exposed to in vivo. Therefore, while in vitro models
are ideal for studying an individual stimulus, they do not
always reflect the complexities of in vivo systems.
Fig 5. In vitro induction of CD80 after LPS and CD163 after glucocorticoid treatment. (A) Flow cytometry examples of CD14 and CD16 expres-
sions on monocyte (MC) subsets before and after 24-h culture with either non-treatment (NT), 1 lmol/l dexamethasone (dex) or 100 ng/ml
lipopolysaccharide (LPS). Cumulative data for (B) the percentage of CD16-expressing I-MCs after treatment, (C) CD64 MFI, (D) CD80 MFI (E)
CD206 MFI and (F) CD163 MFI of C-MC and I-MC following 24-h treatment in vitro of HC peripheral blood MCs. (G) Percentage of CD16-ex-
pressing I-MCs after treatment, (H) CD163 MFI and (I) CD206 MFI on C-MC and I-MC after 24-h in vitro treatment of MCs from patients with
newly diagnosed (ND) or chronic immune thrombocytopenia (ITP). Sample size = 8 HCs, 4 untreated newly diagnosed ITP, 4 chronic ITP,
mean  SD. [Colour figure can be viewed at wileyonlinelibrary.com]
E. L. Williams et al.
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It has been widely reported that both patients with newly
diagnosed and chronic ITP have elevated numbers of IFN-c-
and IL-17A-producing T cells.8 In rheumatoid arthritis, MCs
from inflamed joints enhance IL-17A production from autolo-
gous CD4+ T cells.39 In ITP, CD16+ MCs from patients with
ITP promote the expansion of IFN-c+CD4+ T cells16 and sepa-
rately, IL-17A production has been shown to correlate with
increased CD68+ myeloid cells present in bone marrow of
patients with ITP.40 Alongside this, it has been shown that
M1-like MC-derived macrophages (MDMs) generated from
circulating MCs from patients with ITP augment cytokine
production from CD4+ T cells compared with M2-like MDMs.
Taken together, these data demonstrate that inflammatory
myeloid cells, such as those observed in the present study
upon diagnosis, could contribute to enhanced CD4+ T-cell
activity. In contrast, M2-MDMs from patients with ITP differ-
entiated in the presence of dex for 7 days, similar to the post-
GC MC phenotype observed in our present study, had
decreased CD80 and increased CD163 expression and were
able to suppress CD4+ T-cell proliferation and cytokine pro-
duction,41 suggesting that GC-derived MCs are able to sup-
press CD4+ T-cell responses. Combined with this, patients
with newly diagnosed ITP treated with high-dose dex have
enhanced circulating myeloid-derived suppressor cells
(CD11b+CD33+HLA-DR) and M2-like macrophages
(CD68+CD163+).42 These data suggest that not only are the
circulating peripheral MCs in patients with ITP shifted to
an anti-inflammatory phenotype post-GC treatment, but as
they also give rise to M2-like macrophages these circulating
GC-MCs may contribute to a reduction in overall immune
activation and consequently support disease resolution.
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